Skip to main content

Table 2 Biomarker status in cases that did and did not receive NAT, in biopsy and surgical specimens

From: Effect of neoadjuvant therapy on breast cancer biomarker profile

  

No-NAT group

NAT group

(N = 61)

(N = 78)

Categories

Biopsy

Surgery

p value

Biopsy

Surgery

p value

Estrogen Receptor

Positive

46 (75.4)

46 (75.4)

1

66 (84.6)

64 (82.1)

0.8299

Negative

15 (24.6)

15 (24.6)

12 (15.4)

14 (17.9)

Progesterone Receptor

Positive

42 (68.9)

42 (68.9)

1

60 (76.9)

57 (73.1)

0.7115

Negative

19 (31.1)

19 (31.1)

18 (23.1)

21 (26.9)

HER2

Positive

9 (14.8)

11 (18.0)

0.4165

10 (12.8)

9 (11.5)

0.6616

Negative

47 (77.0)

41 (67.2)

60 (76.9)

59 (75.6)

Ambiguous

5 (8.2)

9 (14.8)

7 (9.0)

10 (12.8)

Ki67 status

Low (< 20%)

21 (34.4)

23 (37.7)

0.5796

19 (24.4)

41 (52.6)

< 0.001

High (≥20%)

37 (60.7)

37 (60.7)

55 (70.5)

37 (47.4)

Unknown

3 (4.9)

1 (1.6)

4 (5.1)

0 (0.0)

  1. NAT Neoadjuvant therapy